|
OMNICOMM SYSTEMS' TRIALMASTERTM ADDED TO KENDLE'S SUITE OF ECLINICAL SOLUTIONS IN MULTI-YEAR ENTERPRISE AGREEMENT.
Fort Lauderdale, FL, September 30, 2009– /Marketwire/ -- OmniComm Systems, Inc. or the "Company" (OTC Bulletin Board:
OMCM ), one of the fastest-growing companies in the EDC
marketplace, today announced that Kendle,
a leading global clinical research organization (CRO), will add OmniComm’s TrialMaster
EDC solution to its current eClinical offerings in a multi-year enterprise-wide
agreement.
"Efficient delivery of high-quality data is critical to Kendle’s continued success
as a leading provider of clinical data management services," said John Fontenault,
Executive Director and Global Head, Clinical Data Management and Technology. "The
addition of the TrialMaster EDC solution to our existing offerings supports Kendle’s
focus on providing our global biopharmaceutical customers with cost-effective access
to the best eClinical solutions to accelerate their Phase I through IV clinical
trials. The TrialMaster platform offers the right mix of functionality to streamline
the study development process and drive efficient study operations."
"We are excited to be working with Kendle to meet the needs of its diverse customer
base," said Stephen Johnson, COO of OmniComm Systems. "Kendle is one of the largest
and most respected and successful top-tier global CROs with extensive eClinical
experience, having conducted more than 250 trials utilizing EDC technologies to
expedite the clinical trials process. We look forward to providing them the eClinical
solutions and services needed to support their continued delivery of best-in-class
clinical development services to their customers."
About Kendle Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization
providing the full range of early- to late-stage clinical development services for
the world's biopharmaceutical industry. Our focus is on innovative solutions that
reduce cycle times for our customers and accelerate the delivery of life-enhancing
drugs to market for the benefit of patients worldwide. As one of the world's largest
global providers of Phase I-IV services, we offer experience spanning more than
100 countries, along with industry-leading patient access and retention capabilities
and broad therapeutic expertise, to meet our customers' clinical development challenges.
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com)
provides customer-driven Internet solutions to pharmaceutical, biotechnology, research
and medical device organizations that conduct life changing clinical trial research.
OmniComm's growing base of satisfied customers is a direct result of the company's
commitment to deliver products and services that ensure ease of use, faster study
build, ease of integration and better performance. OmniComm's client intuitive pricing
model allows companies that range from small, to mid-size to large scale institutions
to safely and efficiently capitalize on their clinical research investments. OmniComm
Systems, Inc has U.S. headquarters in Fort Lauderdale, FL and European headquarters
in Bonn, Germany, with satellite offices in New Jersey, the United Kingdom, and
Russia as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Safe Harbor Disclaimer Statements made by OmniComm included in this release may
constitute forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties
such as the Company's ability to obtain new contracts and accurately estimate net
revenues due to uncertain regulatory guidance, variability in size, scope and duration
of projects, and internal issues at the sponsoring client, integration of acquisitions,
competitive factors, technological development, and market demand. As a result,
actual results may differ materially from any financial outlooks stated herein.
Further information on potential factors that could affect the Company's financial
results can be found in the Company's Reports on Form 10-K and 10-Q filed with the
Securities and Exchange Commission. The Company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information, future
events, or otherwise.
CONTACT: Stephen Johnson at: + 1 954-377-1726
Back
|
